Radiation Oncologists Converge on Capitol Hill to Push for Payment Reform

Why It Matters

The proposed payment reforms aim to stabilize radiation oncology practices, preserve access to life‑saving cancer treatment, and curb the financial pressures driving consolidation in the specialty. Successful legislation could set a precedent for value‑based reimbursement across other high‑cost medical fields.

Key Takeaways

• Two‑thirds of radiation oncologists report pay cuts of 10%+ since Jan 1.
• Medicare reimbursement for radiation oncology down 27% since 2013, inflation‑adjusted.
• ASTRO’s Radiation Oncology Case Rate Act has ~30 congressional co‑sponsors.
• Over 140 medical groups back the case‑rate reform proposal.
• Prior‑authorization delays threaten cancer care access and clinic solvency.

Pulse Analysis

The radiation oncology community faces a perfect storm of declining Medicare fees, rising operational costs, and increasingly burdensome prior‑authorization requirements. While the specialty treats more than one million Americans annually, its reimbursement has slipped 27% since 2013 when adjusted for inflation—far steeper than most other fields. This erosion threatens the financial viability of community clinics, which are essential for delivering timely radiation therapy to patients outside major academic centers.

ASTRO’s push for the Radiation Oncology Case Rate Act reflects a broader shift toward value‑based care. By moving away from fee‑for‑service models that reward volume, the legislation would pay a fixed amount per treatment episode, aligning incentives with outcomes and reducing administrative overhead. The bill’s bipartisan support—nearly 30 co‑sponsors and endorsement from 140 professional groups—signals growing recognition that the current payment structure jeopardizes both provider sustainability and patient access. If enacted, the case‑rate model could serve as a template for other high‑cost specialties seeking to balance cost containment with quality.

Beyond Medicare reform, ASTRO is lobbying for changes to Medicare Advantage prior‑authorization processes and the Improving Seniors’ Timely Access to Care Act. These measures aim to cut delays that can postpone critical cancer treatment, a factor already linked to poorer survival rates. Together, the legislative agenda addresses immediate financial distress while laying groundwork for a more resilient oncology ecosystem, underscoring the strategic importance of policy advocacy in shaping the future of cancer care.